Hemispherx Biopharma
HEB announced that at the 2^nd International Conference on Biodefense
and Natural Disasters meeting in Orlando, FL on August 22, 2013, Professor Dr.
Juergen A. Richt, DVM, Ph.D., a scientific advisor to Hemispherx, described
his experiments in human lung cells evidencing that Alferon N Injection®, the
only multi-species, natural interferon approved in the U.S. for the treatment
of human refractory HPV genital warts, is biologically active, in low doses,
against various classes of viruses occurring naturally in animals and humans.
Dr. Richt is the Director of the U.S. Department of Homeland Security Center
of Excellence for Emerging and Zoonotic Animal Diseases, the Regents
Distinguished Professor at Kansas State University, and an Eminent Scholar of
Kansas Bioscience Association.
The increasing prevalence of oseltamivir-resistant Influenza A viruses,
particularly H7N9, has been widely reported and is due in large part to the
fact that just a single-step mutation in the neuraminidase gene of this
genetically unstable virus makes it resistant to oseltamivir (Tamiflu,
Relenza). Dr. Richt reported on this instability in 2010 in the peer-reviewed
Journal of General Virology, an international journal.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in